Single-dose granulocyte colony-stimulating factor concomitant with multifractionated dose chemotherapy: A strategy for maintaining dose intensity

Cancer Investigation

Volumn 17, Issue 7, 1999, Pages 547-550

  Lokich, Jacob ^a  

^a Cancer Center of Boston   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; ETOPOSIDE; NAVELBINE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG INDUCED DISEASE; HUMAN; LEUKOPENIA; PHASE 2 CLINICAL TRIAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

EID: 0032862111     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909032865     Document Type: Review

References (5)

1. American Society of Clinical Oncology: Update of recommendations for the use of hematopoietic colony-stimulating factors: evidence-based clinical practice guidelines. J Clin Oncol 14:1957-1960, 1996.
2. Livingston RB, Ellis GK, Gralow JR, et al: Dose-intensive vinorelbine with concurrent granulocyte colony-stimulating factor support in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 15: 1395-1400, 1997.
3. Lokich J, Anderson N, Bern M, et al: Paclitaxel, cisplatin, etoposide combination chemotherapy: a comparison of dose intensity in two multifractionated dose schemes. Eur J Cancer 34:664-667, 1998.
4. Lokich J, Anderson N, Bern M, et al: Phase I-II study of multifractionated combination chemotherapy for advanced non-small cell lung cancer; taxol, platinol, navelbine (TPN). Cancer 85:499-503, 1999.
5. Lokich J: Multifractionated dosing for cancer chemotherapy: a novel schedule and a work in progress. Cancer Invest 17:551-554, 1999.